Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer

Investigational New Drugs

Volumn 29, Issue 5, 2011, Pages 1057-1065

  Weekes, Colin D ^a   Nallapareddy, Sujatha ^a   Rudek, Michelle A ^b   Norris Kirby, Alexis ^b   Laheru, Daniel ^b   Jimeno, Antonio ^a   Donehower, Ross C ^b   Murphy, Kathleen M ^b   Hidalgo, Manuel ^b   Baker, Sharyn D ^c   Messersmith, Wells A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c St Judes Children's Research Hospital   (United States)

Author keywords

ATM; Capecitabine; Gemcitabine; Pancreatic cancer; RecQ1; Thymidine synthase enhancer region (TYMS)

Indexed keywords

ATM PROTEIN; CAPECITABINE; RECQ HELICASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALLELE; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DNA DETERMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ENHANCER REGION; FATIGUE; FEMALE; GENETIC SCREENING; GENOTYPE; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DEMOGRAPHY; ENZYMOLOGY; GENETICS; HOMOZYGOTE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEMOGRAPHY; DEOXYCYTIDINE; ENHANCER ELEMENTS, GENETIC; FEMALE; FLUOROURACIL; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 84856072698     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9413-7     Document Type: Article

References (37)

1. American Cancer Society (2009) Cancer facts and figures
2. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE et al (2002) Pancreatic cancer. Curr Probl Cancer 26(4):176-275
3. Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL et al (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44(5):1039-1046
4. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indications. J Gastrointest Surg 4(6):567-579
5. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403-2413
6. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol 25(16):2212-2217
7. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960-1966
8. Volker H, Quietzcsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24(24):3946-3952
9. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23(15):3509-3516
10. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M et al (2005) A phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23(31):8033-8040
11. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem J-L et al (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27(13):2231-2237
12. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JHM, Grochow LB et al (2002) Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. JNCI Cancer Spectrum 94:1883-1888
13. Johnston PG, Drake JC, Trepel J, Allegra C (1992) Immunological quantitation of Thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52:4306-4312
14. Johnston PG, Lenz HJ, Leichman CG, Danenberg K, Allegra CJ, Danenberg PV et al (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412
15. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S et al (1997) Quantitation of intratumoral Thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229
16. Horie N, Aiba H, Katsuhiko O, Hojo H, Takeishi K (1995) Functional analysis of DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197
17. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz H-J et al (2003) A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the Thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898-2904
18. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786
19. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz H-J (2002) Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17:46-49
20. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L et al (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291-297
21. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20(1):160-164
22. Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27(33):5513-5518
23. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4(5):307-314
24. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):7-12
25. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L et al (2006) Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24(11):1720-1728
26. Okazaki T, Jiao L, Chang P, Evans DB, Abbruzzese JL, Li D (2008) Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 14(7):2042-2048
27. Xu Y, Grem JL (2003) Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783(1):273-285
28. Besnard T, Renée N, Etienne-Grimaldi MC, François E, Milano G (2008) Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 870(1):117-120
29. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD et al (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23(17):3906-3911
30. Laheru D, Croghan G, Bukowski R, Rudek M, Messersmith W, Erlichman C et al (2008) A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin Cancer Res 14(17):5602-5609
31. Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA et al (2005) Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 23(4):889-898
32. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AS, Gordon RJ et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22-29
33. Parikh PJ, Mahasittiwat P, Flexhman JW, Tan B, Mutch MG, Myerson RJ et al (2009) Predictors of complete pathologic response on a prospective locally advanced rectal cancer trial. J Clin Oncol Abst 453. Proceedings of ASCO Gastrointestinal Cancer Symposium
34. Zhang Z, Shi Q, Sturgis EM, Spitz MR, Hong WK, Wei Q (2004) Thymidylate synthase 5' and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 10:7903-7910
35. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML (2005) Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:2509-2516
36. Shi Q, Zhang A, Neumann AS, Li G, Spitz MR, Wei Q (2005) Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 26:649-656
37. Javle MM, Okazaki T, Wolff RA, Varadhachary G, Ho L, Crane CH et al (2008) Combined effect of single nucleotide polymorphisms (SNPs) of gemcitabine metabolic genes on pancreatic cancer survival and drug toxicity. J Clin Oncol Abst 126. Proceedings ASCO Gastrointestinal Cancers Symposium